Organon & Co. (OGN)

Market Cap	3.72B
Revenue (ttm)	6.40B
Net Income (ttm)	864.00M
Shares Out	257.54M
EPS (ttm)	3.33
PE Ratio	4.34
Forward PE	3.71
Dividend	$1.12 (7.75%)
Ex-Dividend Date	Feb 24, 2025

Volume	3,111,747
Open	15.04
Previous Close	14.91
Day's Range	14.42 - 15.07
52-Week Range	13.87 - 23.10
Beta	0.72
Analysts	Hold
Price Target	20.80 (+43.95%)
Earnings Date	Feb 13, 2025

About OGN

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple o...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 10,000
• Stock Exchange: NYSE
• Ticker Symbol: OGN
• Website: https://www.organon.com

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Analyst Forecast

According to 5 analysts, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $20.8, which is an increase of 43.95% from the latest price.

Price Target

$20.8

(43.95% upside)

Analyst Consensus: Hold